-
Mashup Score: 6
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
PURPOSETrastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic #BreastCancer: The Randomized Noninferiority Phase III EMERALD Trial ➡️ https://t.co/7LjfmGWIB3 #bcsm
-
-
Mashup Score: 8Treatment of Pleural Mesothelioma: ASCO Guideline Update - 20 day(s) ago
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Treatment of Pleural #Mesothelioma: ASCO Guideline Update https://t.co/XEK9SOYe6B
-
-
Mashup Score: 33
PURPOSENeoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable #LungCancer: https://t.co/llj34czKCy Co-authored by @DrMarkAwad #lcsm
-
-
Mashup Score: 8Treatment of Pleural Mesothelioma: ASCO Guideline Update - 21 day(s) ago
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Treatment of Pleural #Mesothelioma: ASCO Guideline Update https://t.co/XEK9SOYe6B
-
-
Mashup Score: 19
PURPOSEDatopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Datopotamab Deruxtecan in Advanced or Metastatic Non– Small Cell Lung Cancer with Actionable Genomic Alterations: Results from the Phase II TROPION-Lung05 Study. Co-authored by @sands_jacob #LungCancer #nsclc ➡️ https://t.co/gl6fT7WCT0
-
-
Mashup Score: 14
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell #lymphoma: https://t.co/Tak8ZRC8J2 Authored by @nancybartlettMD https://t.co/oC6PYCO91w #lymsm
-
-
Mashup Score: 14
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell #lymphoma: https://t.co/Tak8ZRC8J2 Authored by @nancybartlettMD https://t.co/oC6PYCO91w #lymsm
-
-
Mashup Score: 11
The ASCO Journals Editorial Fellowship is designed to introduce oncology fellows (or their local equivalent) to the peer review, editing, and publishing of medical research manuscripts in journals. Fellows get a direct and immersive experience into how a manuscript is handled, from submission to final decision. This will include the opportunity to critically review papers with the supervision of assigned editors who will serve as their mentors. This program is mostly virtual and can be done in conjunction
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
🤝 New to peer review? Apply for the @ASCO Trainee Reviewer Mentoring Program. Applications close on February 28th ➡️ https://t.co/wiV5KKirGu #mentoring #PeerReview
-
-
Mashup Score: 7Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823) - 1 month(s) ago
PURPOSEThe TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children’s Oncology Group ADVL1823): https://t.co/DphG9CGG3g #childhoodcancer #pedcsm
-
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline ➡️ https://t.co/MgAnOtWjTg #ProstateCancer #pcsm